ERBB2 and neoplasm: Pre-clinical studies evaluating the efficacy of combining anti-PD-1 blockade with Her2-targeting T cells showed significantly enhanced CAR-T cell function in two different in vivo tumor models using Her2 + sarcoma and breast cancer [120].